Precision BioSciences Inc (DTIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Precision BioSciences Inc (DTIL) has a cash flow conversion efficiency ratio of -0.157x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.94 Million) by net assets ($76.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Precision BioSciences Inc to measure how much of total assets are equity-financed.
Precision BioSciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Precision BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Precision BioSciences Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Precision BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precision BioSciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Verb Technology Company Inc
NASDAQ:VERB
|
-0.004x |
|
Niu Technologies
NASDAQ:NIU
|
0.050x |
|
Niko Semiconductor Co Ltd
TWO:3317
|
0.009x |
|
Helloworld Travel Ltd
AU:HLO
|
-0.022x |
|
Soechi Lines Tbk
JK:SOCI
|
0.031x |
|
Les Hotels Bav
PA:ALLHB
|
0.044x |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
-0.024x |
|
Li Peng Enterprise Co Ltd
TW:1447
|
0.034x |
Annual Cash Flow Conversion Efficiency for Precision BioSciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Precision BioSciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Precision BioSciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $92.25 Million | $-65.84 Million | -0.714x | +31.13% |
| 2024-12-31 | $56.39 Million | $-58.45 Million | -1.036x | +76.76% |
| 2023-12-31 | $18.86 Million | $-84.11 Million | -4.460x | -489.06% |
| 2022-12-31 | $60.43 Million | $-45.75 Million | -0.757x | -535.97% |
| 2021-12-31 | $91.17 Million | $-10.85 Million | -0.119x | +93.95% |
| 2020-12-31 | $44.42 Million | $-87.39 Million | -1.967x | -269.47% |
| 2019-12-31 | $138.31 Million | $-73.64 Million | -0.532x | +58.87% |
| 2018-12-31 | $39.96 Million | $-51.72 Million | -1.294x | -241.22% |
| 2017-12-31 | $-26.37 Million | $-24.17 Million | 0.917x | +104.72% |
| 2016-12-31 | $-4.75 Million | $92.27 Million | -19.430x | -- |
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalent… Read more